Surface Logix, Inc., a drug development company, creates and develops novel small molecule drugs with pharmacokinetic and pharmacodynamic properties for human physiology. Its Pharmacomer technology platform creates new chemical entities that respond to various physiological microenvironments in the human body. The company’s products include SLx-2101, a phosphodiesterase 5 inhibitor for the treatment of cardiovascular diseases; SLx-4090, a microsomal triglyceride transfer protein inhibitor for the treatment of dyslipidemia and familial hypercholesterolemia; SLx-2119, a rho kinase inhibitor for the treatment of oncology diseases; and SLx-3XXX, a rho kinase inhibitor for the treatment of inflammatory and fibrotic diseases. Surface Logix was founded in 1999 and is headquartered in Brighton, Massachusetts.